vs
Side-by-side financial comparison of Entrada Therapeutics, Inc. (TRDA) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $19.1M, roughly 1.1× Americas Gold & Silver Corp). Americas Gold & Silver Corp runs the higher net margin — -82.3% vs -84.4%, a 2.1% gap on every dollar of revenue. On growth, Americas Gold & Silver Corp posted the faster year-over-year revenue change (-28.0% vs -65.2%). Entrada Therapeutics, Inc. produced more free cash flow last quarter ($-39.7M vs $-41.3M).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
TRDA vs USAS — Head-to-Head
Income Statement — Q1 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $19.1M |
| Net Profit | $-17.3M | $-15.7M |
| Gross Margin | — | 34.2% |
| Operating Margin | -106.0% | — |
| Net Margin | -84.4% | -82.3% |
| Revenue YoY | -65.2% | -28.0% |
| Net Profit YoY | -173.8% | 2.8% |
| EPS (diluted) | $-0.42 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $19.1M | ||
| Q1 25 | $20.6M | — | ||
| Q4 24 | $37.4M | — | ||
| Q3 24 | $19.6M | $26.5M | ||
| Q2 24 | $94.7M | — | ||
| Q1 24 | $59.1M | — | ||
| Q4 23 | $41.8M | — | ||
| Q3 23 | $43.7M | — |
| Q3 25 | — | $-15.7M | ||
| Q1 25 | $-17.3M | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-14.0M | $-16.2M | ||
| Q2 24 | $55.0M | — | ||
| Q1 24 | $23.5M | — | ||
| Q4 23 | $-9.5M | — | ||
| Q3 23 | $35.5M | — |
| Q3 25 | — | 34.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 23.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q3 25 | — | — | ||
| Q1 25 | -106.0% | — | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -110.7% | — | ||
| Q2 24 | 56.4% | — | ||
| Q1 24 | 35.7% | — | ||
| Q4 23 | 11.7% | — | ||
| Q3 23 | 32.0% | — |
| Q3 25 | — | -82.3% | ||
| Q1 25 | -84.4% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | -71.7% | -60.9% | ||
| Q2 24 | 58.1% | — | ||
| Q1 24 | 39.7% | — | ||
| Q4 23 | -22.8% | — | ||
| Q3 23 | 81.1% | — |
| Q3 25 | — | — | ||
| Q1 25 | $-0.42 | — | ||
| Q4 24 | $-0.20 | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $1.55 | — | ||
| Q1 24 | $0.68 | — | ||
| Q4 23 | $-0.23 | — | ||
| Q3 23 | $1.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.8M | $39.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $417.3M | $50.2M |
| Total Assets | $486.5M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $39.1M | ||
| Q1 25 | $67.8M | — | ||
| Q4 24 | $101.2M | — | ||
| Q3 24 | $78.0M | — | ||
| Q2 24 | $185.3M | — | ||
| Q1 24 | $68.4M | — | ||
| Q4 23 | $67.6M | — | ||
| Q3 23 | $51.9M | — |
| Q3 25 | — | $50.2M | ||
| Q1 25 | $417.3M | — | ||
| Q4 24 | $428.7M | — | ||
| Q3 24 | $422.4M | $53.1M | ||
| Q2 24 | $429.9M | — | ||
| Q1 24 | $269.4M | — | ||
| Q4 23 | $242.4M | — | ||
| Q3 23 | $246.7M | — |
| Q3 25 | — | $234.7M | ||
| Q1 25 | $486.5M | — | ||
| Q4 24 | $526.3M | — | ||
| Q3 24 | $554.6M | — | ||
| Q2 24 | $582.0M | — | ||
| Q1 24 | $510.8M | — | ||
| Q4 23 | $469.2M | — | ||
| Q3 23 | $485.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.5M | $-12.5M |
| Free Cash FlowOCF − Capex | $-39.7M | $-41.3M |
| FCF MarginFCF / Revenue | -192.9% | -216.5% |
| Capex IntensityCapex / Revenue | 5.6% | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-58.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-12.5M | ||
| Q1 25 | $-38.5M | — | ||
| Q4 24 | $-31.6M | — | ||
| Q3 24 | $-24.3M | $2.4M | ||
| Q2 24 | $39.8M | — | ||
| Q1 24 | $-25.5M | — | ||
| Q4 23 | $-4.0M | — | ||
| Q3 23 | $-24.5M | — |
| Q3 25 | — | $-41.3M | ||
| Q1 25 | $-39.7M | — | ||
| Q4 24 | $-32.2M | — | ||
| Q3 24 | $-24.9M | $-11.2M | ||
| Q2 24 | $38.8M | — | ||
| Q1 24 | $-26.4M | — | ||
| Q4 23 | $-5.0M | — | ||
| Q3 23 | $-25.9M | — |
| Q3 25 | — | -216.5% | ||
| Q1 25 | -192.9% | — | ||
| Q4 24 | -86.2% | — | ||
| Q3 24 | -127.3% | -42.2% | ||
| Q2 24 | 41.0% | — | ||
| Q1 24 | -44.6% | — | ||
| Q4 23 | -11.9% | — | ||
| Q3 23 | -59.3% | — |
| Q3 25 | — | 150.8% | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 3.3% | 51.2% | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.4% | — | ||
| Q4 23 | 2.3% | — | ||
| Q3 23 | 3.3% | — |
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -27.94× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | -1.09× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
